» Articles » PMID: 31660902

Dynamic Interaction of Genetic Risk Factors and Cocaine Abuse in the Background of Parkinsonism - a Case Report

Overview
Journal BMC Neurol
Publisher Biomed Central
Specialty Neurology
Date 2019 Oct 30
PMID 31660902
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Parkinsonism is a complex multifactorial neurodegenerative disorder, in which genetic and environmental risk factors may both play a role. Among environmental risk factors cocaine was earlier ambiguously linked to Parkinsonism. Former single case reports described Parkinsonism in chronic cocaine users, but an epidemiological study did not confirm an increased risk of Parkinson's disease. Here we report a patient, who developed Parkinsonism in young age after chronic cocaine use, in whom a homozygous LRRK2 risk variant was also detected.

Case Presentation: The patient was investigated because of hand tremor, which started after a 1.5-year period of cocaine abuse. Neurological examination suggested Parkinsonism, and asymmetrical pathology was confirmed by the dopamine transporter imaging study. The genetic investigations revealed a homozygous risk allele in the LRRK2 gene. After a period of cocaine abstinence, the patient's symptoms spontaneously regressed, and the dopamine transporter imaging also returned to near-normal.

Conclusions: This case report suggests that cocaine abuse indeed might be linked to secondary Parkinsonism and serves as an example of a potential gene-environmental interaction between the detected LRRK2 risk variant and cocaine abuse. The reversible nature of the DaTscan pathology is a unique feature of this case, and needs further evaluation, whether this is incidental or can be a feature of cocaine related Parkinsonism.

Citing Articles

Chronic Cocaine Use and Parkinson's Disease: An Interpretative Model.

Carbone M, Maremmani I Int J Environ Res Public Health. 2024; 21(8).

PMID: 39200714 PMC: 11354226. DOI: 10.3390/ijerph21081105.


Role of the gut-brain axis in HIV and drug abuse-mediated neuroinflammation.

Ray S, Sil S, Kannan M, Periyasamy P, Buch S Adv Drug Alcohol Res. 2024; 3:11092.

PMID: 38389809 PMC: 10880759. DOI: 10.3389/adar.2023.11092.


Prevention of Parkinson's Disease: From Risk Factors to Early Interventions.

Ng M, Chan B, Koh R, Ng K, Chye S CNS Neurol Disord Drug Targets. 2023; 23(6):746-760.

PMID: 37326115 DOI: 10.2174/1871527322666230616092054.


Psychomotor Symptoms in Chronic Cocaine Users: An Interpretative Model.

Cenci D, Carbone M, Callegari C, Maremmani I Int J Environ Res Public Health. 2022; 19(3).

PMID: 35162918 PMC: 8835199. DOI: 10.3390/ijerph19031897.


Neuroprotection or Neurotoxicity of Illicit Drugs on Parkinson's Disease.

Ferreira C, Almeida C, Tenreiro S, Quintas A Life (Basel). 2020; 10(6).

PMID: 32545328 PMC: 7344445. DOI: 10.3390/life10060086.

References
1.
Kakish J, Lee D, Lee J . Drugs That Bind to α-Synuclein: Neuroprotective or Neurotoxic?. ACS Chem Neurosci. 2015; 6(12):1930-40. DOI: 10.1021/acschemneuro.5b00172. View

2.
Asser A, Taba P . Psychostimulants and movement disorders. Front Neurol. 2015; 6:75. PMC: 4403511. DOI: 10.3389/fneur.2015.00075. View

3.
Deik A, Saunders-Pullman R, San Luciano M . Substance of abuse and movement disorders: complex interactions and comorbidities. Curr Drug Abuse Rev. 2012; 5(3):243-53. PMC: 3966544. DOI: 10.2174/1874473711205030243. View

4.
Varrone A, Dickson J, Tossici-Bolt L, Sera T, Asenbaum S, Booij J . European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging. 2012; 40(2):213-27. DOI: 10.1007/s00259-012-2276-8. View

5.
Zheng Y, Liu Y, Wu Q, Hong H, Zhou H, Chen J . Confirmation of LRRK2 S1647T variant as a risk factor for Parkinson's disease in southern China. Eur J Neurol. 2010; 18(3):538-40. DOI: 10.1111/j.1468-1331.2010.03164.x. View